This study investigates the antidepressant-like effects of cannabidiol (CBD) in mice, highlighting its role in serotonin modulation. Administering 10 mg/kg of CBD induced significant antidepressant effects in the forced swim test (FST), comparable to fluoxetine (10 mg/kg) and desipramine (5 mg/kg). Lower doses of CBD (7 mg/kg) combined with sub-effective
This study examines the antidepressant-like effects of cannabidiol (CBD) in mice, demonstrating that a dose of 30 mg/kg significantly reduced immobility in the forced swimming test, an effect comparable to the standard antidepressant imipramine. The study suggests that CBD’s effects are mediated through 5-HT1A receptor activation, as they were blocked
This study explores the therapeutic potential of cannabidiol (CBD) for brain disorders, focusing on its interaction with multiple brain targets and evaluating alternative drug delivery methods to enhance its efficacy. Oral CBD administration is limited by slow absorption and low bioavailability due to first-pass metabolism, prompting interest in alternative delivery
This study examined the antidepressant-like effects of cannabidiol (CBD) in rodent models, demonstrating that a single dose (7-30 mg/kg) produced rapid and sustained reductions in depressive-like behaviors. The effects were associated with increased expression of synaptic proteins (synaptophysin and PSD95), elevated brain-derived neurotrophic factor (BDNF) levels, and enhanced spine density
This study examined the antidepressant-like effects of chronic administration of synthetic cannabidiol (CBD) in mice. Over seven days, mice received CBD at doses of 10, 30, or 100 mg/kg, and depressive-like behaviors were assessed using the forced swim test (FST). The study found that 100 mg/kg of CBD significantly reduced
This review examines preclinical studies on cannabidiol (CBD) and its potential antidepressant effects, focusing on molecular mechanisms and interactions with neurotransmitter systems such as serotonergic, glutamatergic, and endocannabinoid pathways. CBD has been shown to enhance brain-derived neurotrophic factor (BDNF) signaling, promote synaptogenesis in the medial prefrontal cortex, and support neurogenesis
This systematic review explores the broad therapeutic potential of cannabidiol (CBD) in the treatment of psychiatric disorders such as anxiety, depression, and psychosis. It synthesizes data from multiple in vivo studies and highlights that CBD exerts its beneficial effects through several mechanisms, including facilitating 5-HT1A receptor-mediated neurotransmission, potentiating anandamide-mediated pathways
This 2024 review investigates the antidepressant mechanisms of cannabidiol (CBD), focusing on its interaction with serotonin and BDNF-TrkB signaling pathways. CBD may exert rapid and sustained antidepressant effects by increasing serotonin release in the prefrontal cortex via action on dorsal raphe nuclei and enhancing BDNF-TrkB signaling, which promotes neuroplasticity. These
This 2019 animal study investigated the pharmacokinetics and antidepressant-like effects of cannabidiol (CBD) in mice subjected to chronic mild stress. The study found that a single intravenous dose of CBD had a half-life of 3.9 hours and oral bioavailability of only 8.6%, suggesting IV delivery may be more efficient. Both
This 2024 animal study evaluated the antidepressant-like effects of repeated cannabidiol (CBD) treatment in Flinders Sensitive Line (FSL) rats, a genetic model of depression. Rats treated with CBD (10 mg/kg intraperitoneally for 7 days) showed reduced depressive-like behaviors in the Forced Swimming Test without changes in locomotor activity. CBD enhanced
